BIOCRYST PHARM
BIOCRYST PHARM operates in Diversified Metals & Mining.
BIOCRYST PHARM (BO1) - Total Assets
Latest total assets as of September 2024: €491.25 Million EUR
Based on the latest financial reports, BIOCRYST PHARM (BO1) holds total assets worth €491.25 Million EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BIOCRYST PHARM - Total Assets Trend (2016–2023)
This chart illustrates how BIOCRYST PHARM’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BIOCRYST PHARM - Asset Composition Analysis
Current Asset Composition (December 2023)
BIOCRYST PHARM's total assets of €491.25 Million consist of 95.9% current assets and 4.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 21.4% |
| Accounts Receivable | €56.95 Million | 11.0% |
| Inventory | €28.68 Million | 5.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how BIOCRYST PHARM's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIOCRYST PHARM's current assets represent 95.9% of total assets in 2023, an increase from 74.6% in 2016.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2023, down from 24.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 11.0% of total assets.
BIOCRYST PHARM Competitors by Total Assets
Key competitors of BIOCRYST PHARM based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
BIOCRYST PHARM - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - BIOCRYST PHARM generates 0.64x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BIOCRYST PHARM is currently not profitable relative to its asset base.
BIOCRYST PHARM - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.78 | 5.54 | 1.78 |
| Quick Ratio | 2.73 | 5.21 | 1.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €273.56 Million | € 411.70 Million | € 72.01 Million |
BIOCRYST PHARM - Advanced Valuation Insights
This section examines the relationship between BIOCRYST PHARM's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.0% |
| Total Assets | €516.96 Million |
| Market Capitalization | $70.21K USD |
Valuation Analysis
Below Book Valuation: The market values BIOCRYST PHARM's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BIOCRYST PHARM's assets decreased by 6.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BIOCRYST PHARM (2016–2023)
The table below shows the annual total assets of BIOCRYST PHARM from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €516.96 Million | -6.01% |
| 2022-12-31 | €550.00 Million | -6.49% |
| 2021-12-31 | €588.15 Million | +75.72% |
| 2020-12-31 | €334.71 Million | +90.96% |
| 2019-12-31 | €175.28 Million | +19.37% |
| 2018-12-31 | €146.84 Million | -17.62% |
| 2017-12-31 | €178.26 Million | +98.40% |
| 2016-12-31 | €89.85 Million | -- |